Bothell-based BioLife Solutions, Inc. announced Oct. 21 that Frederick, MD based RoosterBio, Inc., has adopted the Company’s CryoStor clinical grade cryopreservation freeze media to commercialize RoosterBio’s human bone marrow-derived, adult mesenchymal stem cell (hMSC) products.

“We are very pleased that RoosterBio has chosen CryoStor as the cryopreservation media for its high volume adult hMSC products,” BioLife President & CEO Mike Rice said. “A growing number of cell suppliers are realizing the benefits CryoStor enables in improved yield and quality of cryopreserved cells and cell lines. End users conducting research on potential clinical applications of mesenchymal stem cells will continually seek to source very high quality cells from suppliers like RoosterBio. It is very satisfying to see the biopreservation efficacy and quality footprint of CryoStor being recognized by RoosterBio, an emerging and very promising supplier of clinically relevant cells.”

RoosterBio’s hMSC products are being used by researchers throughout the world to accelerate the development of cellular therapies and engineered tissues targeting major diseases and disorders affecting millions of patients each year.

“Our team has a long history of observing improved post-preservation cell survival and functional recovery enabled by the use of CryoStor, a clinical grade freeze media engineered to better protect cells from preservation-induced injury and death,” President & CEO of RoosterBio Jon Rowley said. “Our customers are benefitting from increased quantity and quality of cells following cryopreservation, with rapid recovery and regrowth – saving precious time and money in their development programs.”